Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 OutlookGlobeNewsWire • 02/26/26
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/18/26
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewsWire • 02/12/26
Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue ResultsGlobeNewsWire • 01/12/26
TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026GlobeNewsWire • 11/12/25
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the YearGlobeNewsWire • 11/06/25
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/06/25
Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025GlobeNewsWire • 10/22/25
Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive GrowthGlobeNewsWire • 10/15/25
Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q's Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality ControlBusiness Wire • 09/17/25
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCAGlobeNewsWire • 09/10/25
Cytek Biosciences, Inc. (CTKB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/10/25
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow CytometerGlobeNewsWire • 05/29/25
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 05/28/25
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/08/25